Antimalarial drugs chloroquine and sulphodoxine − pyrimethamine resistance was a setback to malaria control.
Studies reveal that withdrawal of there can lead to recovery of sensitivity of parasites over time.
In Rwanda chloroquine susceptibility recovery appears slow but sulphodoxine − pyrimethamine resistance remains high after years of withdrawal.
Elucidating the determinants of these drug-related genomic adaptations over time and exposure to varying drug pressures in Rwanda is needed.